Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$13.36

-0.38 (-2.77%)

16:03
06/19/18
06/19
16:03
06/19/18
16:03

Kala Pharmaceuticals to submit NDA for KPI-121 to FDA in H2

Kala Pharmaceutical provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease. The company announced that it plans to submit a New Drug Application to the U.S. Food and Drug Administration during the second half of 2018. The NDA will include data from three clinical trials studying approximately 2000 patients, including one Phase 2 trial and two Phase 3 efficacy and safety trials. In addition, based upon the recommendation of the FDA, Kala plans to initiate an additional Phase 3 clinical trial evaluating KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The company plans to initiate the new trial, STRIDE 3, in the third quarter of 2018. Top-line results for STRIDE 3 are anticipated in the fourth quarter of 2019. The company has conducted a comprehensive analysis of data generated in its previous three clinical trials and believes it has identified key factors that contributed to the differences observed in the results from STRIDE 2 compared to those of STRIDE 1 and Phase 2. The company has integrated these factors into the trial design of STRIDE 3, which the company believes will improve the probability of success for the trial. Kala remains committed to developing KPI-121 0.25% for the millions of patients suffering from dry eye disease for whom there is currently no product approved for the temporary relief of signs and symptoms of the disease.

  • 24

    Aug

KALA Kala Pharmaceuticals
$13.36

-0.38 (-2.77%)

01/25/18
WELS
01/25/18
NO CHANGE
Target $19
WELS
Outperform
Kala Pharmaceuticals price target lowered to $19 from $24 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Kala Pharmaceuticals to $19 from $24 on valuation after the shares dropped following mixed results from the two pivotal Phase III trials of its dry eye treatment, KPI-121. The analyst believes Kala's shares have the opportunity to outperform as investors shift their near-term focus to the company's post-surgical ocular steroid which has an August 2018 PDUFA. He reiterates an Outperform rating on the stock.
01/05/18
WELS
01/05/18
NO CHANGE
WELS
Outperform
Kala dry eye trial results mixed but positive, says Wells Fargo
After Kala Pharmaceuticals reported that KPI-121 demonstrated statistically significant improvements in the primary sign and symptom endpoints in one Phase 3 trial but missed for the primary symptom endpoint in another trial, Wells Fargo analyst David Maris said the mixed data "complicates things" but still show a positive drug profile for KPI-121. He would expect the shares to be down on this data, but also believes some of the risk seems to have been in expectations given the stock having been down recently. Maris keeps an Outperform rating on Kala shares, which are down 24% in morning trading.
11/17/17
JPMS
11/17/17
NO CHANGE
Target $35
JPMS
Overweight
Kala offers 'compelling' risk/reward into dry eye data, says JPMorgan
After meeting with management, JPMorgan analyst Chris Schott continues to see a "compelling" risk/reward for Kala Pharmaceuticals shares ahead of Phase 3 data for KPI-121 0.25% reading out later this year. The shares can rally to $40-plus share on positive Phase 3 dry eye data, versus downside to high single digits or low teens on a negative readout, Schott tells investors in a research note. The analyst views Kala as an attractive ophthalmology pure play and keeps an Overweight rating on the shares with a $35 price target.
10/25/17
WELS
10/25/17
NO CHANGE
Target $24
WELS
Outperform
Kala new drug application an 'important milestone,' says Wells Fargo
Wells Fargo analyst David Maris calls Kala Pharmaceuticals' on-time new drug application for Inveltys an "important milestone" since the company is development-stage beginning the transition to a commercially-focused business. The topical has the potential to be the first FDA approved ocular corticosteroid with two-times per day dosing for the treatment of inflammation and pain following ocular surgery, Maris tells investors in a research note. He sees lower than average commercial and regulatory risk for Inveltys as the active steroid is well-known and already approved in postsurgical ocular pain and inflammation. He sees sales of the topical growing to $100M in 2021 and keeps an Outperform rating Kala with a $24 price target.

TODAY'S FREE FLY STORIES

11:08
02/21/19
02/21
11:08
02/21/19
11:08
General news
3-Month Bill Announcement CUSIP Number data reported »

3-Month Bill Announcement…

MNST

Monster Beverage

$58.64

-0.07 (-0.12%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Options
Monster Beverage option volume spikes to 3X daily average amid active trading »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LIVN

LivaNova

$98.56

-1.32 (-1.32%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Recommendations
LivaNova analyst commentary  »

Piper says Japanese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

UBCP

United Bancorp

$10.95

(0.00%)

11:04
02/21/19
02/21
11:04
02/21/19
11:04
Hot Stocks
United Bancorp raises quarterly cash dividend to 13.25c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.59

-1.29 (-1.29%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
LivaNova announces national reimbursement in Japan for Perceval valve for AVD »

LivaNova announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

KO

Coca-Cola

$45.48

0.36 (0.80%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
Coca-Cola announces new share repurchase program for up to 150M shares »

The Coca-Cola board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

KO

Coca-Cola

$45.49

0.37 (0.82%)

11:02
02/21/19
02/21
11:02
02/21/19
11:02
Hot Stocks
Coca-Cola raises quarterly dividend to 40c per share from 39c per share »

The Coca-Cola board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

11:00
02/21/19
02/21
11:00
02/21/19
11:00
General news
EIA natural gas storage change for week ending February 15 »

Earlier, gas inventories…

11:00
02/21/19
02/21
11:00
02/21/19
11:00
General news
Crude inventories for week of February 15 »

Crude oil inventories…

KR

Kroger

$28.82

0.07 (0.24%)

11:00
02/21/19
02/21
11:00
02/21/19
11:00
Options
One-day call buyers in Kroger »

One-day call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 07

    Mar

UAA

Under Armour

$21.26

-0.02 (-0.09%)

, UA

Under Armour

$19.22

0.025 (0.13%)

10:52
02/21/19
02/21
10:52
02/21/19
10:52
Periodicals
Under Armour CEO questioned by board about ties with MSNBC anchor, WSJ says »

A number of current and…

UAA

Under Armour

$21.26

-0.02 (-0.09%)

UA

Under Armour

$19.22

0.025 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

10:50
02/21/19
02/21
10:50
02/21/19
10:50
General news
U.S. corporate bond update: issuance continues apace today »

U.S. corporate bond…

COUP

Coupa Software

$92.39

-1.36 (-1.45%)

10:50
02/21/19
02/21
10:50
02/21/19
10:50
Options
Short-term hedge opened in Coupa Software »

Short-term hedge opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

10:50
02/21/19
02/21
10:50
02/21/19
10:50
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

OHRP

Ohr Pharmaceutical

$2.01

(0.00%)

10:47
02/21/19
02/21
10:47
02/21/19
10:47
Hot Stocks
Ohr Pharmaceutical regains compliance with Nasdaq listing requirements »

Ohr Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$5.81

4.385 (307.72%)

, MRK

Merck

$79.79

0.35 (0.44%)

10:46
02/21/19
02/21
10:46
02/21/19
10:46
Downgrade
Immune Design, Merck rating change  »

Immune Design downgraded…

IMDZ

Immune Design

$5.81

4.385 (307.72%)

MRK

Merck

$79.79

0.35 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 11

    Apr

  • 18

    May

  • 17

    Jun

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

ANET

Arista Networks

$266.95

-3.58 (-1.32%)

10:45
02/21/19
02/21
10:45
02/21/19
10:45
Conference/Events
Arista Networks has a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

10:45
02/21/19
02/21
10:45
02/21/19
10:45
General news
Breaking General news story  »

Week of 2/15 EIA…

NKE

Nike

$83.97

-0.87 (-1.03%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
On The Fly
Analyst sees 'minimal' lasting damage to Nike brand after Duke star's shoe splits »

Shares of Nike (NKE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFT

Weatherford

$0.79

-0.0263 (-3.21%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
Options
10.1K Weatherford Mar 1 calls trade as shares drop 2c to 80c »

10.1K Weatherford Mar 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

10:40
02/21/19
02/21
10:40
02/21/19
10:40
General news
Treasury Action: yields have cheapened despite some disappointing data »

Treasury Action: yields…

KAR

KAR Auction

$48.30

1.56 (3.34%)

10:37
02/21/19
02/21
10:37
02/21/19
10:37
Upgrade
KAR Auction rating change  »

KAR Auction upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.